Medical and nursing home costs: From cognitively unimpaired through dementia.


Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
03 2022
Historique:
revised: 02 05 2021
received: 20 08 2020
accepted: 17 05 2021
pubmed: 6 9 2021
medline: 21 4 2022
entrez: 5 9 2021
Statut: ppublish

Résumé

Efforts to model the cost-effectiveness of managing/modifying cognitive impairment lack reliable, objective, baseline medical, and nursing-home (NH) costs. A stratified-random sample of Olmsted County, MN, residents ages 70-89 years (N = 3545), well-characterized as cognitively unimpaired, mild cognitive impairment (MCI), or dementia, were followed forward ≤1 year in provider-linked billing data and the Centers for Medicare & Medicaid Services NH assessments. Direct medical/nursing home/medical + NH costs were estimated. Costs were stratified by vital status and NH-use intensity (NH days/follow-up days [0%, 1% to 24%, 25% to 99%, and 100%]). Between-category mean-annual cost differences were adjusted for patient characteristics and follow-up days. Costs/follow-up day distributions differed significantly across cognitive categories. Mean costs/follow-up days were 2.5 to 18 times higher for decedents versus survivors. Among all persons with MCI, <9% with any NH use accounted for 18% of all total annual medical + NH costs. Adjusted-between-category comparisons revealed significantly higher medical and medical + NH costs for MCI versus cognitively unimpaired. Cost-effectiveness for managing/modifying both MCI and dementia should consider end-of-life costs and NH-use intensity. Results can help inform cost-effectiveness models, predict future-care needs, and aid decision-making by individuals/providers/payers/policymakers.

Identifiants

pubmed: 34482623
doi: 10.1002/alz.12400
pmc: PMC8897513
mid: NIHMS1709873
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

393-407

Subventions

Organisme : NIA NIH HHS
ID : R01 AG034676
Pays : United States
Organisme : NIA NIH HHS
ID : R33 AG058738
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG006786
Pays : United States

Informations de copyright

© 2021 the Alzheimer's Association.

Références

J Gerontol. 1982 May;37(3):323-9
pubmed: 7069156
J Am Geriatr Soc. 2013 Mar;61(3):396-402
pubmed: 23414481
JAMA Intern Med. 2019 Feb 1;179(2):161-166
pubmed: 30575846
Alzheimers Dement. 2015 Aug;11(8):917-32
pubmed: 25858682
Alzheimers Dement. 2009 May;5(3):215-26
pubmed: 19362885
Am J Manag Care. 2009 Jul;15(7):437-45
pubmed: 19589011
Alzheimers Dement. 2011 Jan;7(1):53-60
pubmed: 21255743
Med Care. 1994 Jul;32(7):668-85
pubmed: 8028403
Appl Health Econ Health Policy. 2013 Aug;11(4):407-13
pubmed: 23700254
Int J Geriatr Psychiatry. 2008 Sep;23(9):963-71
pubmed: 18416451
Pharmacoeconomics. 2009;27(6):507-17
pubmed: 19640013
Alzheimers Dement. 2017 Oct;13(10):1077-1080
pubmed: 28935202
Alzheimers Dement. 2017 Mar;13(3):312-321
pubmed: 28063281
N Engl J Med. 1997 Nov 13;337(20):1466-70
pubmed: 9380105
Health Aff (Millwood). 2014 Apr;33(4):596-604
pubmed: 24711320
Neuroepidemiology. 2008;30(1):58-69
pubmed: 18259084
N Engl J Med. 2013 Apr 4;368(14):1326-34
pubmed: 23550670
J Am Geriatr Soc. 2019 Feb;67(2):269-276
pubmed: 30315744
J Intern Med. 2014 Mar;275(3):214-28
pubmed: 24605806
Health Econ. 2006 Oct;15(10):1091-107
pubmed: 16518793
Alzheimers Dement. 2021 Mar;17(3):327-406
pubmed: 33756057
J Am Geriatr Soc. 2020 Jun;68(6):1319-1324
pubmed: 32187655
Alzheimers Dement. 2019 Oct;15(10):1309-1321
pubmed: 31402324
Am J Epidemiol. 2014 Aug 15;180(4):414-23
pubmed: 24859276
Alzheimers Dement. 2017 Mar;13(3):201-204
pubmed: 28232007
Neuroepidemiology. 2010;34(1):34-42
pubmed: 19893327
Am J Geriatr Psychiatry. 2021 Feb;29(2):179-191
pubmed: 32646634
Mayo Clin Proc. 2012 Feb;87(2):151-60
pubmed: 22305027
Alzheimers Dement. 2017 Mar;13(3):217-224
pubmed: 27693186
BMC Health Serv Res. 2017 Jun 12;17(1):396
pubmed: 28606088
Gerontologist. 2018 Mar 19;58(2):e97-e106
pubmed: 29106531
J Psychiatr Res. 2009 Jan;43(4):411-31
pubmed: 18579155
Int J Epidemiol. 2012 Dec;41(6):1614-24
pubmed: 23159830
J Am Geriatr Soc. 2018 Dec;66(12):2274-2281
pubmed: 30462843
J Health Econ. 1998 Jun;17(3):247-81
pubmed: 10180918
J Am Med Dir Assoc. 2017 May 01;18(5):438-441
pubmed: 28214236
Am J Alzheimers Dis Other Demen. 2013 Jun;28(4):384-92
pubmed: 23687180
J Alzheimers Dis. 2020;75(2):437-450
pubmed: 32250304
J Am Geriatr Soc. 2016 Aug;64(8):1549-57
pubmed: 27295430
PLoS One. 2014 Apr 07;9(4):e93372
pubmed: 24710075

Auteurs

Kirsten Hall Long (KH)

K Long Health Economics Consulting, LLC, St. Paul, Minnesota, USA.

Carin Smith (C)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.

Ronald Petersen (R)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Jane Emerson (J)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.

Jeanine Ransom (J)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.

Michelle M Mielke (MM)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Steven Hass (S)

Department of Health Economics and Outcomes Research, AbbVie, North Chicago, Illinois, USA.

Cynthia Leibson (C)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH